摘要
目的:探讨索利那新联合坦索罗辛治疗良性前列腺增生伴膀胱过度活动症的有效性。方法:对我院2009年1月-2011年12月收治的良性前列腺增生伴膀胱过度活动症患者217例进行回顾性比较分析。结果:①对照组治疗前后IPSS评分(19.6±2.3,15.5±2.5)、排尿期症状评分(5.3±1.4,3.5±1.7)、Qmax(13.7±4.1,16.6±4.0),治疗前后比较有显著差异。②实验组治疗前后IPSS评分(19.5±2.3,9.7±2.3)、储尿期症状评分(13.8±1.8,5.6±1.7)、OABSS(10.3±1.7,5.4±1.2)、Qmax(14.1±3.9,17.1±3.4),治疗前后比较有显著差异。③治疗后实验组与对照组IPSS评分(9.7±2.3,15.5±2.5)、储尿期症状评分(5.6±1.7,12.2±1.8)、OABSS(9.8±2.6,5.4±1.2)比较有显著差异。实验组与对照组排尿期症状评分(3.3±1.2,3.5±1.7)、Qmax(17.1±3.4,16.6±4.0)、残余尿量(36.7±16.8,35.6±12.4)比较无显著差异。结论:索利那新联合坦索罗辛治疗良性前列腺增生伴膀胱过度活动症疗效优于单用坦索罗辛。
Objective:To evaluate the efficacy of combination therapy of solifenacin and tamsulosin for benign prostatic hyperplasia with overactive bladder.Methods:217 cases with OAB and coexisting BPH were analized.Results:The valus of IPSS(19.6±2.3 vs 15.5±2.5)、the voiding symptom score(5.3±1.4 vs 3.5±1.7)、Q max(13.7±4.1 vs 16.6±4.0) improved significantly after treatment in tamsulosin.The valus of IPSS(19.5±2.3 vs 9.7±2.3)、the storage symptom score(13.8±1.8 vs 5.6±1.7)、OABSS(9.8±2.6 vs 5.4±1.2)、 Q max(14.1±3.9 vs 17.1±3.4) improved significantly after treatment in combination group.The value of IPSS(9.7±2.3 vs 15.5±2.5),the storage symptom score(5.6±1.7 vs 12.2±1.8) and OABSS(9.8±2.6 vs 5.4±1.2) improved significantly in combination group than those in tamsulosin group.There were no difference between groups in value of voiding symtom score,Qmax and residual urine volume.Conclusion:It is effective for patients with BPH and OAB to accept combination therapy of tamsulosin and solifenacin.
出处
《中国保健营养（下半月）》
2012年第4期743-744,共2页
China Health Care & Nutrition
